ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 259 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $10,666,449 | -10.3% | 410,406 | -1.3% | 0.07% | -12.7% |
| Q1 2024 | $11,891,393 | -15.6% | 415,783 | -9.7% | 0.08% | -15.1% |
| Q4 2023 | $14,084,475 | +1659.8% | 460,277 | +1950.8% | 0.09% | +1228.6% |
| Q2 2023 | $800,352 | +14.1% | 22,444 | +29.7% | 0.01% | +16.7% |
| Q4 2022 | $701,688 | -53.3% | 17,300 | -61.9% | 0.01% | -53.8% |
| Q3 2022 | $1,502,000 | +311.5% | 45,422 | +338.4% | 0.01% | +225.0% |
| Q2 2022 | $365,000 | -54.9% | 10,361 | -41.1% | 0.00% | -42.9% |
| Q1 2022 | $809,000 | -35.1% | 17,600 | -6.3% | 0.01% | -36.4% |
| Q4 2021 | $1,246,000 | -20.8% | 18,787 | -1.1% | 0.01% | -35.3% |
| Q2 2021 | $1,573,000 | +524.2% | 18,996 | +399.8% | 0.02% | +466.7% |
| Q1 2021 | $252,000 | -78.6% | 3,801 | -75.2% | 0.00% | -81.2% |
| Q4 2020 | $1,176,000 | -12.6% | 15,321 | -51.0% | 0.02% | -38.5% |
| Q3 2020 | $1,346,000 | +20.8% | 31,251 | -61.8% | 0.03% | -56.7% |
| Q2 2018 | $1,114,000 | +129.7% | 81,900 | +21.8% | 0.06% | +66.7% |
| Q1 2018 | $485,000 | – | 67,257 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ELEMENT CAPITAL MANAGEMENT LLC | 142,649 | $618,000 | 0.25% |
| ING GROEP NV | 808,229 | $3,500,000 | 0.07% |
| A.R.T. Advisors, LLC | 232,470 | $1,006,000 | 0.05% |
| OppenheimerFunds, Inc. | 3,000,000 | $12,990,000 | 0.02% |
| Edge Wealth Management LLC | 10,000 | $43,000 | 0.01% |
| First Allied Advisory Services, Inc. | 61,000 | $264,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 200,000 | $866,000 | 0.01% |
| MILLENNIUM MANAGEMENT LLC | 1,272,138 | $5,508,000 | 0.01% |
| D. E. Shaw & Co., Inc. | 971,768 | $4,208,000 | 0.01% |
| Virtu Financial LLC | 18,008 | $78,000 | 0.00% |